<DOC>
	<DOCNO>NCT02322749</DOCNO>
	<brief_summary>A Study ass , reference selumetinib capsule , drug level variant selumetinib capsule comparable , assess drug level differ another variant Selumetinib Healthy Male Volunteers .</brief_summary>
	<brief_title>A Study Assess Relative Bioavailability Process Variants Selumetinib Healthy Male Volunteers</brief_title>
	<detailed_description />
	<criteria>1.Provision write informed consent 2.Healthy male volunteer age 18 45 year 3.Calculated creatinine clearance ( CrCL ) &gt; 50 mL/minute use CockcroftGault formula 4.Healthy volunteer sexual partner could become pregnant agree use 2 highly effective method contraception . Healthy volunteer sexual partner pregnant agree use effective method contraception ( barrier method ) first administration 12 week last administration investigational product . Healthy volunteer avoid sperm donation study 12 week last administration investigational product 5.Use nicotine contain product least 3 month prior screen 6.For inclusion genetic component study , healthy volunteer provide write informed consent genetic research . 1.Healthy male volunteer Japanese non Japanese Asian , Indian ethnicity 2.Any one parent grandparent ( maternal paternal ) Japanese nonJapanese Asian Indian 3.Involvement planning and/or conduct study . 4.Previous randomisation treatment present study 5.Participation another clinical study within 3 month Visit 1 , participation method development study 1 month Visit 1 . 6.Current past history central serous retinopathy retinal vein thrombosis , intraocular pressure great 21 mmHg uncontrolled glaucoma 7.Any clinically significant disease disorder may put healthy volunteer risk participation study , influence result study influence healthy volunteer 's ability participate study 8.Any clinically relevant abnormal finding physical examination , haematology , clinical chemistry , urinalysis , vital sign 12lead ECG Visit 1 , may put healthy volunteer risk participation study . 9.Use prescribed medication overthecounter drug ( include herbal remedy ) know moderate strong cytochrome P450 ( CYP ) 3A4 CYP2C19 inducer inhibitory effect 30 day prior first administration investigational product follow visit 10.Use prescribed medication overthecounter drug ( include herbal remedy , vitamin mineral ) within 2 week 5 time half life , whichever longer , respective drug prior Visit 2 , exception occasional use acetaminophen ( paracetamol TYLENOLÂ® ) overthecounter adrenergic nasal spray relief nasal congestion . No medication know prolong QT/corrected QT interval ( QTc ) interval allow 11.Excessive intake caffeine contain drink food . 12.Any intake grapefruit Seville oranges product contain grapefruit Seville oranges within 7 day first admission 13.A definite suspect personal history intolerance hypersensitivity drug and/or excipients 14.Plasma donation blood donation/blood loss great 500 mL 3 month prior screen 15.History , current alcohol drug abuse . 16.A suspected/manifested infection accord International Air Transport Association ( IATA ) Categories A B infectious substance 17.Healthy male volunteer agree use least 2 effective method contraception 18.Positive result screen human immunodeficiency virus ( HIV ) and/or hepatitis B and/or hepatitis C 19.Planned inpatient surgery , dental procedure hospitalisation study 20.Healthy male volunteer , opinion Principal Investigator , participate study 21.Healthy male volunteer LVEF &lt; 55 % 22.Previous bone marrow transplant 23.Whole blood transfusion within 120 day genetic sample collection</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>bioequivalence</keyword>
	<keyword>bioavailability</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>Phase I</keyword>
	<keyword>AZD6244</keyword>
	<keyword>cancer</keyword>
</DOC>